STTR Phase I: Development of Bacterial Glycorandomization Hosts

这个小企业技术转移研究第一阶段项目开发了生产糖增强（糖苷）化合物文库和最终治疗先导所需的方法。糖的附着物被认为是制造治疗相关小分子的有效途径。红霉素和阿霉素等含糖药物的例子表明，糖如何将无活性分子转变为抗菌或抗癌药物。寻找正确的基因改造细胞系统，以高效高产地生产小分子糖增强化合物，这是利用糖增强药物发现的第一步，超出了自然提供的范围。这项研究更广泛的影响体现在糖增强疗法提供的巨大潜力中。糖是调节人体大量生物过程和途径的关键分子，在疾病和药物作用中起着重要作用。该项目将大大简化和降低糖增强小分子疗法的制造、筛选和商业规模化的成本。

This Small Business Technology Transfer Research Phase I project develops methodology needed for the production of sugar enhanced (glycosidic) compound libraries and final therapeutic leads. Sugar attachments have been identified as a powerful way to make therapeutically relevant small molecules. Examples of drugs with sugar attachments such as erythromycin and doxorubicin show how sugars can change inactive molecules into antibacterial or anticancer drugs. Finding the correct genetically altered cell-based systems needed for efficient high yield production of small molecule sugar enhanced compounds is the first phase at exploiting sugar enhanced drug discovery beyond what Nature has provided.The broader impacts of this research are found in the enormous potential that sugar enhancement provides to therapeutics. Sugars are critical molecules that regulate a vast array of biological processes and pathways in the human body and play fundamental roles in diseases as well as in drug action. This project will greatly expand the ease and reduce the cost of making, screening and commercially scaling sugar-enhanced small molecule therapeutics.